(Q43084689)

13 November 2017

0 references

Current trends of anticancer immunochemotherapy (English)

1 reference

13 November 2017

3

1 reference

13 November 2017

4

Lorenzo Galluzzi

1 reference

13 November 2017

Erika Vacchelli

1

0 references

author name string

Nicole Prada

series ordinal

2

1 reference

13 November 2017

13 June 2013

1 reference

13 November 2017

1 reference

13 November 2017

2

1 reference

13 November 2017

e25396

1 reference

13 November 2017

6

1 reference

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

13 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Trial watch: DNA vaccines for cancer therapy

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Regulation of ligands for the NKG2D activating receptor

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Trial watch: Peptide vaccines in cancer therapy

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Mitochondria: master regulators of danger signalling

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Trial watch: Dendritic cell-based interventions for cancer therapy

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Immunogenic cell death in cancer therapy

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Trial Watch: Monoclonal antibodies in cancer therapy

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Combining immunotherapy and targeted therapies in cancer treatment

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

The secret ally: immunostimulation by anticancer drugs

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Cancer immunotherapy--revisited

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Immune parameters affecting the efficacy of chemotherapeutic regimens

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3716761

Trial watch: Monoclonal antibodies in cancer therapy

25 May 2018

1 reference

Crossref

https://api.crossref.org/works/10.4161%2FONCI.25396

Cyclophosphamide induces differentiation of Th17 cells in cancer patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23894726

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/ONCI.25396

1 reference

release_rmm27vhxt5acjme4t27ui24fmi

13 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rmm27vhxt5acjme4t27ui24fmi

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMCID

3716761

1 reference

13 November 2017

1 reference

PMCID

3716761